about
Antagonistic regulation, yet synergistic defense: effect of bergapten and protease inhibitor on development of cowpea bruchid Callosobruchus maculatusCryptosporidium Lactate Dehydrogenase Is Associated with the Parasitophorous Vacuole Membrane and Is a Potential Target for Developing TherapeuticsGene discovery, evolutionary affinity and molecular detection of Oxyspirura petrowi, an eye worm parasite of game birdsAnnotated draft genome sequences of three species of Cryptosporidium: Cryptosporidium meleagridis isolate UKMEL1, C. baileyi isolate TAMU-09Q1 and C. hominis isolates TU502_2012 and UKH1.Transcriptome analysis reveals unique metabolic features in the Cryptosporidium parvum Oocysts associated with environmental survival and stressesGiardia fatty acyl-CoA synthetases as potential drug targetsDifferential Gene Expression and Protein Localization of Cryptosporidium parvum Fatty Acyl-CoA Synthetase Isoforms.Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.Seroprevalence of five parasitic pathogens in pregnant women in ten Caribbean countries.Multiyear Survey of Coccidia, Cryptosporidia, Microsporidia, Histomona, and Hematozoa in Wild Quail in the Rolling Plains Ecoregion of Texas and Oklahoma, USA.A unique hexokinase in Cryptosporidium parvum, an apicomplexan pathogen lacking the Krebs cycle and oxidative phosphorylation.Molecular cloning and differential expression in tissues of a tyrosinase gene in the Pacific oyster Crassostrea gigas.What is your diagnosis? Corneal scrape from a dog.Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs.The existing drug vorinostat as a new lead against cryptosporidiosis by targeting the parasite histone deacetylases.Transcriptomic response of cowpea bruchids to N-acetylglucosamine-specific lectins.The Action of the Hexokinase Inhibitor 2-deoxy-d-glucose on Cryptosporidium parvum and the Discovery of Activities against the Parasite Hexokinase from Marketed Drugs
P50
Q28482430-11D7BB4A-4E52-4756-88ED-742A5BDC899AQ28550913-8160B950-87BC-4AB8-9505-A3BE359D3311Q28657695-37465365-D1CE-4D2B-A870-6EDEE8CBCC58Q33609094-667AB0DA-3E46-487F-B70B-3050C667D6A0Q34484657-9B559F0D-16C1-484C-9913-C21A7FBA3B63Q35877105-7BE1A62C-45ED-4EEC-BBBA-B3A933316A4CQ36642424-BDA5D117-655F-464D-B3D2-2E6975335690Q37671934-9D338C3E-C620-4518-9F89-F676282BF872Q39252216-8E9F8E37-30B0-4A5A-AFAD-F0258CB788BCQ40660719-D14BD7D8-1B6E-47A9-9D3D-01AC283460F9Q41741437-B8F99920-7C91-4724-B5D1-215B3AF18F7CQ45000748-85B87737-E529-4DF4-8391-C28D652AC998Q48098087-F60C979B-369F-42A0-8918-28CE0A5ED20CQ50136314-FB91374D-0E4C-4D24-8BE9-A73A25EDFC90Q50193112-9D7CAE2F-8BBD-4DD2-839E-0DBE15A119EDQ50694719-85D605E3-A755-4AEA-AA56-84725FAAB9F3Q91480366-9A2723E5-BCA3-46ED-B04A-A219C73A60E3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fengguang Guo
@ast
Fengguang Guo
@en
Fengguang Guo
@es
Fengguang Guo
@nl
type
label
Fengguang Guo
@ast
Fengguang Guo
@en
Fengguang Guo
@es
Fengguang Guo
@nl
prefLabel
Fengguang Guo
@ast
Fengguang Guo
@en
Fengguang Guo
@es
Fengguang Guo
@nl
P106
P31
P496
0000-0002-3742-7214